Intercure

INCR
4.5302.03% ( +0.090 )
Closed: Oct 23, 16:00:01 (EDT)

Current ValuationThe current P/E ratio is -5.10, below the reasonable range, cheaper than 87.96% of the time in the past 5 years, and the industry ranks 171/256, the industry Median -1.11.

-5.1xP/E
Stock price$4.53Earnings per share$-0.89

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-61.21x154.30%$63.94B
BAYZFUSBayer Aktiengesellschaft
-24.08x--$48.51B
BAYRYUSBayer
-23.99x--$48.34B
VTRSUSViatris
-50.34x107.68%$20.67B
ELANUSElanco Animal Health
-56.54x129.36%$11.25B
VREOFUSVIREO GROWTH INC
-115.63x--$7.76B
AXSMUSAxsome Therap
-39.64x21.12%$7.60B
CURLFUSCuraleaf Holdings, Inc.
-115.94x--$6.03B
BLTEUSBelite Bio
-57.96x29.87%$5.93B
MANEUSVeraDermics
-55.60x97.44%$5.80B
DFTXUSDefinium Therapeutics
-13.55x54.55%$4.79B
EWTXUSEdgewise Therapeutics
-21.65x207.38%$4.27B
RGCUSRegencell Bioscience
-324.76x--$3.80B
AMLXUSAmylyx Pharmaceuticals
-22.45x1.76%$3.41B
ELVNUSEnliven Therapeutics
-28.72x5.59%$3.04B
TARSUSTarsus Pharmaceuticals
-64.39x256.39%$2.99B
BHCUSBausch Health
-2.19x569.84%$2.41B
SUPNUSSupernus Pharma
-21.53x66.18%$2.37B
MBXUSMBX Biosciences
-22.40x31.12%$2.34B
PRGOUSPerrigo
-1.28x100.10%$2.21B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.